MedPath

Intravenous Sodium Bicarbonate Verifies Intravenous Position of Catheters in Spontaneously Breathing Adult Volunteers

Phase 2
Conditions
Infiltration
Extravasation
Interventions
Drug: sodium bicarbonate 4.2%
Drug: diluted sodium bicarbonate 2.1%
Drug: normal saline
Registration Number
NCT01458873
Lead Sponsor
Sheba Medical Center
Brief Summary

Vascular access in patients carries a significant risk of accidental extravasation of intravenous (IV) fluids and medications with the potential for tissue injury. This prospective controlled study assessed the diagnostic utility of using intravenous diluted sodium bicarbonate to confirm placement of IV catheters in volunteers . Diluted sodium bicarbonate or 0.9% normal saline, will be injected in a randomized order while end-tidal carbon dioxide in the exhaled air will be monitored. The investigators hypothesize that the injected bicarbonate will dissolve into carbon dioxide and water and cause a transient increase in the measured exhaled CO2.

The effect is unique to bicarbonate and will not appear once normal saline is injected. the safety of the administration of bicarbonate on the metabolic profile of the volunteers will be assessed by measurement of venous blood pH and electrolytes.

Detailed Description

Vascular access in patients carries a significant risk of accidental extravasation of intravenous (IV) fluids and medications with the potential for tissue injury. This prospective controlled study assessed the diagnostic utility of using intravenous diluted sodium bicarbonate to confirm placement of IV catheters in volunteers . Diluted sodium bicarbonate or 0.9% normal saline, will be injected in a randomized order while end-tidal carbon dioxide in the exhaled air will be monitored. The investigators hypothesize that the injected bicarbonate will dissolve into carbon dioxide and water and cause a transient increase in the measured exhaled CO2. Arbitrary increase of more than 10%in end-tidal carbon dioxide is considered as a positive response.

The effect is unique to bicarbonate and will not appear once normal saline is injected. the safety of the administration of bicarbonate on the metabolic profile of the volunteers will be assessed by measurement of venous blood pH and electrolytes.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • ASA I,II
  • no cardiovascular or respiratory disease
Exclusion Criteria
  • ASA > II
  • Cardiovascular disease
  • Respiratory disease
  • renal failure
  • metabolic alkalosis

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
sodium bicarbonate 4.2%sodium bicarbonate 4.2%sodium bicarbonate 4.2% 50 m"l
sodium bicarbonate 2.1%diluted sodium bicarbonate 2.1%sodium bicarbonate 2.1% 1 50 m"l
normal salinenormal saline50 m"l normal saline
Primary Outcome Measures
NameTimeMethod
transient increase in end tidal carbon dioxide4-12 seconds

Once sodium bicarbonate is injected the measured end-tidal carbon dioxide will transiently increase by at least 10% of baseline

Secondary Outcome Measures
NameTimeMethod
Change in venous blood pH10-20 minutes

Blood pH and will be measured prior and ten minutes after the injections

Subjective adverse symptoms associated with injection of sodium bicarbonate1 minute

The subjective symptoms as well as hemodynamic changes associated with the injection of sodium bicarbonate will be recorded

change in venous blood sodium10- 20 minutes

blood sodium level will be measured before and 10-20 minutes after the end of the injections.

change in venous blood bicarbonate level10-20 minutes

blood level of bicarbonate will be measured before and 10-20 minutes after the injection.

change in venous blood potasium level10-20 minutes

venous blood potasium level will be measured before and 10-20 minutes after injection

Trial Locations

Locations (1)

Sheba Medical Center

🇮🇱

Tel Hashomer, Israel

© Copyright 2025. All Rights Reserved by MedPath